the hanover insurance group inc. - THG
THG
Close Chg Chg %
170.02 0.92 0.54%
Closed Market
170.94
+0.92 (0.54%)
Volume: 348.64K
Last Updated:
Jan 20, 2026, 3:59 PM EDT
Company Overview: the hanover insurance group inc. - THG
THG Key Data
| Open $169.54 | Day Range 169.00 - 171.87 |
| 52 Week Range 147.76 - 188.18 | Market Cap $6.05B |
| Shares Outstanding 35.58M | Public Float 35.23M |
| Beta 0.33 | Rev. Per Employee N/A |
| P/E Ratio 9.82 | EPS $17.59 |
| Yield 214.76% | Dividend $0.95 |
| EX-DIVIDEND DATE Dec 12, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 263.96K |
THG Performance
| 1 Week | 0.00% | ||
| 1 Month | -8.02% | ||
| 3 Months | -2.76% | ||
| 1 Year | 8.75% | ||
| 5 Years | 45.29% |
THG Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 200.125 | |
| Number of Ratings | 10 | Current Quarters Estimate | 4.454 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 16.836 | |
| Last Quarter’s Earnings | 4.88 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 18.18 | Next Fiscal Year Estimate | 17.605 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 7 | 9 | 8 |
| Mean Estimate | 4.45 | 3.49 | 16.84 | 17.60 |
| High Estimates | 4.61 | 3.89 | 17.40 | 18.51 |
| Low Estimate | 4.25 | 2.76 | 16.40 | 16.75 |
| Coefficient of Variance | 3.03 | 11.21 | 1.91 | 3.50 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 5 | 4 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for The Hanover Insurance Group Inc. - THG
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for The Hanover Insurance Group Inc. - THG
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Dec 4, 2025 | John Conner Roche President and CEO; Director | 123,715 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $185.91 per share | 22,999,855.65 |
| Dec 4, 2025 | Bryan J. Salvatore Executive Vice President | 25,678 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $185.91 per share | 4,773,796.98 |
| Dec 4, 2025 | Dennis F. Kerrigan Executive Vice President | 9,740 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $185.91 per share | 1,810,763.40 |
| Dec 4, 2025 | Jeffrey Mark Farber Executive Vice President | 45,855 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $185.91 per share | 8,524,903.05 |
| Apr 2, 2025 | Richard William Lavey Executive Vice President | 39,079 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | Willard T. Lee Executive Vice President | 5,455 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | Denise Tinger M. Lowsley Executive Vice President | 5,034 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | David J. Lovely Executive Vice President | 2,254 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 124,278 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $175.03 per share | 21,752,378.34 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 124,414 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 124,715 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $77.91 per share | 9,716,545.65 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 124,414 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $175 per share | 21,772,450.00 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 9,207 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 2, 2025 | John Conner Roche President and CEO; Director | 8,906 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 27, 2025 | Warren Ellison Barnes SVP & Princpl. Accntg. Officer | 3,265 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Jeffrey Mark Farber Executive Vice President | 46,432 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Denise Tinger M. Lowsley Executive Vice President | 5,158 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Richard William Lavey Executive Vice President | 9,377 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Richard William Lavey Executive Vice President | 38,916 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | David J. Lovely Executive Vice President | 3,539 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |